Male Infertility Market Insight
The global Male Infertility Market was valued at $216 million, and is expected to reach $301.5 million by 2020, supported by a CAGR of 5%. The inability of a couple to conceive within 12 months of unprotected intercourse is called infertility. According to National Institutes of Health in the U.S. there are approximately >2 million infertile couples of which about 40% accounts to male infertility. The most common type of male infertility is the idiopathic infertility and infertility due to varicocele. The basic treatments involved in male infertility are surgery, treatment for problems in intercourse, hormone treatment and ART technology.
There is a steady increase in the global infertility rates both in the developed and developing nations. The changing life style, delayed pregnancy and aging are few of the factors driving the global infertility cases. The report excludes basic male infertility treatments such as surgery, treatment for problems in intercourse and hormonal treatment. The report focuses on male infertility and its treatment techniques with focus on drugs and devices. There are various techniques that are used in the diagnosis of the male infertility such as DNA fragmentation, oxidative stress, CASA (computer assisted semen analysis), sperm penetration assay, sperm agglutination and microscopic examination. The DNA fragmentation is an emerging technique which has already gained popularity and is accepted as a routine technique in the developed countries. The technique is yet to gain popularity in the developing regions and yet to be used as a routine technique due to the cost hindrance.
The couple’s inability to conceive within one year of unprotected intercourse is defined as infertility. Approximately 15% of couples in North America and Europe in a given year are unable to conceive.
Fertility depends on male, female and both male and female factors. Among the infertility cases, 8% cases are due to male factors, 37% cases are due to female factors, 35% cases are both female and male factors and 5% cases are unexplained factors in both the genders.
Causes of male infertility
Fertility in male is defined as the normal functioning of the pituitary gland, hypothalamus and testes. Thus, various conditions can lead to infertility:
- 1-2% of the cases are due to problems in the hypothalamus
- 10-20% of the cases are due to blockage of the sperm pathway
- 30-40% of the cases are due to improper functions of the testes
- 40%-50% of the cases are unidentifiable
Evaluation of male infertility
An evaluation is done by studying the patient’s health and medical history. Physical examination comes under the evaluation tests which includes the measurement of weight, height, muscle distribution, assessment of body fat, visual observation of breasts and genitals and inspection of hair pattern and skin. For example, in cases of testosterone deficiency, there is loss of body and facial hair with decrease in testis size. The various other conditions that affect fertility are absence of vas deferens, varicocele and epididymis thickening.
The semen analysis technique is done to check the fertility level of the collected semen sample and to identify the reasons for infertility. The various techniques used in semen analysis are
- DNA fragmentation
- Oxidative stress analysis
- Sperm penetration assay
- Sperm agglutination assay
- Computer assisted semen analysis (CASA)
- Sperm agglutination
- Microscopic examination
- Others (biochemical assessment tests)
The DNA fragmentation technique and oxidative stress analysis test has a significant usage in the semen analysis technique. The DNA fragmentation test is expected to be the most widely used in the routine semen analysis test, when compared to the oxidative stress analysis test. This is due to DNA fragmentation test’s ability to measure DNA damage example SCSA (Sperm chromatin structure assay) a method used in DNA fragmentation testing, is a sensitive one and can measure DNA damage in 20% of couples with unexplained infertility. The oxidative stress analysis is not widely used as DNA fragmentation due to the alternative methods such as IVF/ICSI, for achieving pregnancy. The microscopic examination test is a routine mandatory test used in all cases, but the test is expected to be replaced by the CASA due to its automation.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global Male infertility market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the Male infertility market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2015 to 2020 is provided to enable the stakeholders to capitalize on the prevailing Male infertility market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of Male infertility used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the male infertility market.
Reason for the Study
- To study the various techniques used to treat male infertility
- To identify the benefits of the new techniques over the conventional techniques
- To study the treatment trends in various geographic regions
Male Infertility Market, by Techniques Report Highlights
| Aspects | Details |
 By Techniques |
|
 By Geography |
|
 By Key Market Players |
|
Analyst Review
Male infertility is defined as the inability of a man to impregnate his female partner after a year of unprotected intercourse. There are various types of infertilities such as idiopathic infertility, hormone deficiency, sperm autoimmunity, obstructive azoospermia, etc. The factors driving the male infertility market are the changing lifestyles which include the delaying of fathering children, consumption of alcohol, smoking, obesity, etc. The other factors being environmental factors and age related factors. The quality of the sperm decreases as individual ages, i.e. after 40years. The major limitation of the market is the repeated failures in treatment cycles that would lead to physical and emotional impact on the patient, and few patients would discontinue the treatments. The other limitation being the social taboo due to which the patients might not opt for treatment. Only 15% of infertile male opt for infertility treatment, this low percentage is due to the guilt and embarrassment felt by the patients and their unwillingness to speak about it. The opportunity of this market is the increase in awareness levels as most men are slowly opting for infertility treatment. The other opportunity of this market is medical tourism.
This market research report is an effort to provide the clear picture of the state of the market and sub markets over the next seven years. The report provides micro level analysis of the factors affecting the market, key market trends and industry drives and challenges for the better understanding of the market structure. The presentation of the market dynamics, competitive scenario and developments will enable marketers to aptly design their growth strategies and have competitive edge. Moreover, assessment of the top investment pockets and winning strategies will help in channelizing their investments in the right directions to garner better proceeds.
The total market value of Male Infertility Market is US $301.5 million by 2020.
The forcast period for Male Infertility Market is 2015 to 2020
The market value of Male Infertility Market in 2015 is $ 216 million.
The base year is 2014 in Male Infertility Market
ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B
Loading Table Of Content...
